Comments? What is the view of this 2012 study and its conclusions?
europeanurology.com/article...
Jeff
Comments? What is the view of this 2012 study and its conclusions?
europeanurology.com/article...
Jeff
For as long as I have been alive, management of PCa has been by targeting the androgen receptor [AR] axis. Dutasteride inhibits the conversion of testosterone [T] to dihydrotestosterone [DHT]. Castration therapy (via Lupron, etc, or surgery) inhibits DHT by near elimination of T.
Makes absolute sense IMO, that Dutasteride would slow progression.
When I asked for Avodart (Dutasteride), my doctor thought I would have a problem with my insurance company - it is only FDA-approved for BPH. But I didn't. It's surprising that it isn't used after biochemical recurrence following curative treatment - & in active surveilance. It has none of the morbidity associated with AR axis drugs.
-Patrick